Spectral Medical Inc
TSX:EDT

Watchlist Manager
Spectral Medical Inc Logo
Spectral Medical Inc
TSX:EDT
Watchlist
Price: 0.495 CAD 2.06% Market Closed
Market Cap: 140m CAD
Have any thoughts about
Spectral Medical Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-9.7
Current
-10.7
Median
4.2
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-9.7
=
Enterprise Value
134.6m CAD
/
EBITDA
-13.8m CAD
All Countries
Close
Market Cap EV/EBITDA
CA
Spectral Medical Inc
TSX:EDT
140m CAD -9.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -220 094.3
US
Abbvie Inc
NYSE:ABBV
316.5B USD 15.5
US
Amgen Inc
NASDAQ:AMGN
141.2B USD 16
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD 21.7
US
Epizyme Inc
F:EPE
94.1B EUR -513.4
AU
CSL Ltd
ASX:CSL
135.7B AUD 19.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD 15.3
US
Seagen Inc
F:SGT
39.3B EUR -58.6
NL
argenx SE
XBRU:ARGX
36B EUR -109.3
EBITDA Growth EV/EBITDA to Growth
CA
Spectral Medical Inc
TSX:EDT
Average EV/EBITDA: 16.4
Negative Multiple: -9.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 094.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.7
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.4 N/A N/A
AU
CSL Ltd
ASX:CSL
19.8
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.3 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-13.3
2-Years Forward
EV/EBITDA
-27.8
3-Years Forward
EV/EBITDA
N/A

See Also

Discover More